GSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible Patients

  • GSK plc GSK announced positive results from a Phase 2a study demonstrating that GSK3036656, an investigational antitubercular agent, was well tolerated and showed early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.
  • The trial included participants with drug-susceptible pulmonary tuberculosis (TB). 
  • Earlier this year, GSK committed to investing £1 billion over the next decade to accelerate R&D on infectious diseases, including TB, that disproportionately impact lower-income countries.
  • The anti-mycobacterial activity was demonstrated in reducing the number of viable TB cells which can multiply (colony forming units - CFU) and an increase in the time to detect bacterial growth in culture (time to positivity - TTP). 
  • In addition, PET CT imaging of the lungs showed a reduction in TB disease over 14 days in all participants taking GSK3036656 30mg.
  • The investigational antitubercular agent will be tested in Phase 2b/c studies in different drug regimens to determine the appropriate partner agents to complement its anti-TB action and the optimal regimen durations. 
  • Price Action: GSK shares are up 3.51% at $32.68 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!